Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.

Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo ...

Novartis Cosentyx meets primary and all secondary endpoints in phase III trial in patients with polymyalgia rheumatica: Basel Thursday, October 23, 2025, 09:00 Hrs [IST] Novartis ...

Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing ...

The Global Healthy Living Foundation (GHLF), parent non-profit of the CreakyJoints® online patient community, today announced ...

MJH Life Sciences acquired BPD Healthcare, a 2025 MM+M Agency 100 honoree. Kenvue said it told the FDA its labeling request is unsupported by scientific evidence and would mark a departure from the ...

Novartis (NVS) today announced that Cosentyx met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial. Cosentyx ...

Levofloxacin-induced myopathy is a relatively under-recognized adverse effect. Here, we present a case of myopathy affecting the iliac and gluteal muscles caused by the administration of levofloxacin.

Autoimmune neuromuscular diseases may sound complex, but understanding them is the first step to getting the right care and ...

A new arthritis treatment in Greensboro is giving patients relief without surgery. One woman says low-dose radiation changed ...

Dr. David Suetholz was an addiction treatment pioneer during the opioid epidemic and a longtime Kenton County coroner. Suetholz was convicted of 12 counts of illegal distribution of controlled ...